Clinical Trial Update: A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation [Phase 3]

View source ↗

Summary

Phase 3 study comparing FK506MR with Prograf (tacrolimus) in kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• FK506MR (tacrolimus (modified-release))
• Prograf (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED